Please assess the completion status of the following clinical trial:

Trial Title: Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Renal transplant recipients who are ≥ 6 months post-day of transplant surgery.~2. Single organ kidney recipient (may be for first or repeat transplant).~3. Age ≥ 30 years of age as of the Day 0 visit.~4. Immunosuppressive regimen consisting of a CNI (cyclosporine \[CsA, Neoral\] or tacrolimus \[TAC, Prograf or Advagraf\], corticosteroids and either MMF (CellCept), EC-MPS (Myfortic), AZA (Imuran) or SRL (Rapamune) at the baseline visit. Patients are to be maintained on the same dose(s) for at least 4 weeks prior to study enrolment.~5. If the patient is taking an MPA immunosuppressant at the time of the screening visit, the MMF (CellCept) dose must be ≤ 1500 mg/day; or the EC-MPS (Myfortic) dose must be ≤ 1080 mg/day.~6. Framingham risk factor score that exceeds the low comparative 10-year CHD risk, based on age and gender.~7. Presence of at least one established CV risk factor at baseline warranting modification of the immunosuppressive regimen including:~   * Hypertension: Blood pressure ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic and/or requiring ≥ 1 antihypertensive medication.~  * Diabetes mellitus: Established diabetes requiring treatment with oral hypoglycemic agents or insulin, or known IFG or IGT based on 75-g oral glucose tolerance testing (2003 Canadian Diabetes Association criteria).~  * Hyperlipidemia: TC ≥ 5.2 mmol/L, or LDL-C ≥ 2.6 mmol/L, or TG ≥ 1.7 mmol/L, or TC:HDL ≥ 4 and/or requiring ≥ 1 anti-hyperlipidemia agent.~8. Willingness and ability to complete protocol requirements.~9. Written informed consent.~Exclusion Criteria:~1. Contraindication to receiving MMF (CellCept) or increasing CellCept dose.~2. Clinically suspected acute rejection (AR) or BPAR within 3 months prior to the baseline visit.~3. Proteinuria ≥ 1 g/24 hours~4. Treatment with AZA (Imuran), EC-MPS (Myfortic) or SRL (Rapamune) and patient or physician decision not to discontinue these agents and switch to MMF (CellCept) at the time of randomization.~5. MDRD (4-variable) eGFR \< 15 mL/min/1.73 m2~6. Patients who currently exceed thresholds for plasma glucose, cholesterol or blood pressure. Patients may be re-considered 1 month after the treatment is in place and no further therapeutic changes are anticipated.~7. Patients who require changes to their blood pressure, blood sugar or blood lipid management between the Screening Visit and Day 0. Patients may be re-considered 1 month after the adjusted treatment is in place and no further therapeutic changes are anticipated.~8. Pregnancy, lactation or (for women of childbearing potential) inability or decision not to use a reliable method of contraception for the entire study duration.~9. Active infection requiring treatment.~10. Treatment with unlicensed investigational drugs, devices or other prohibited medications - see Section 4.4.1~11. Participation in any other interventional clinical trial during the previous 4 weeks or during this trial.~12. History of malignancy, other than non-melanoma skin cancer that has been totally excised and has not recurred for \>2 years.~13. History of psychological illness or condition that could interfere with the patient's ability to understand or comply with the study requirements.~14. Presence of other significant diseases or issues which, in the opinion of the sponsor-investigator, may:~    * Put the patient at risk as a result of study participation~   * Influence the study result~   * Affect the patient's ability to participate in the study~   * Require a change in immunosuppression medication used or a dose change within the next 6 months (unstable renal function, gout that may require treatment with prednisone, etc)~   * Reduce life expectancy. Examples include but are not limited to history of noncompliance and transportation issues that could affect a participant's ability to successfully complete the study requirements. Inability or refusal to provide blood samples, end-stage disease of organs such as lung, liver or heart.~15. Exclusion of patients who are hypersensitive to CellCept (mycophenolate mofetil), mycophenolic acid or any component of the drug).

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CellCept optimization (Type: EXPERIMENTAL): None
- Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues